Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents

被引：66

作者：

Ismail, Rania S. M. ^{[1
]}

Ismail, Nasser S. M. ^{[2
]}

Abuserii, Sahar ^{[4
]}

Abou El Ella, Dalal A. ^{[3
]}

机构：

[1] Egyptian Russian Univ, Pharmaceut Chem Dept, Fac Pharm, Suez Rd, Badr City, Egypt

[2] Future Univ, Pharmaceut Chem Dept, Fac Pharmaceut Sci & Pharmaceut Ind, Cairo 12311, Egypt

[3] Ain Shams Univ, Pharmaceut Chem Dept, Fac Pharm, Cairo 11566, Egypt

[4] Cairo Univ, Dept Pharmaceut Chem, Fac Pharm, Kasr El Aini St, Cairo, Egypt

来源：

FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES | 2016年 / 2卷 / 01期

关键词：

Quinazolines; EGFR inhibitors; Protein kinases; Tyrosine kinase inhibitors;

D O I：

10.1016/j.fjps.2016.02.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Quinazoline derivatives are fused heterocyclic ring systems which have been explored for their inhibitory activity towards various protein kinase enzymes and their role as anticancer agents. The present review to represent the most recent synthetic strategies and medicinal aspects including structure activity relationships of substituted quinazolines as EGFR inhibitors reported to date. (C) 2016 Future University. Production and hosting by Elsevier B.V.

引用

页码：9 / 19

页数：11

共 71 条

[1] Allosteric inhibitors of Bcr-abl-dependent cell proliferation [J].

Adrián, FJ ;

Ding, Q ;

Sim, TB ;

Velentza, A ;

Sloan, C ;

Liu, Y ;

Zhang, GB ;

Hur, W ;

Ding, S ;

Manley, P ;

Mestan, J ;

Fabbro, D ;

Gray, NS .

NATURE CHEMICAL BIOLOGY, 2006, 2 (02) :95-102

[2] Novel series of 8H-quinazolino[4,3-b]quinazolin-8-ones via two Niementowski condensations [J].

Alexandre, FR ;

Berecibar, A ;

Wrigglesworth, R ;

Besson, T .

TETRAHEDRON, 2003, 59 (09) :1413-1419

[3] Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas [J].

Andrews, DW ;

Resnicoff, M ;

Flanders, AE ;

Kenyon, L ;

Curtis, M ;

Merli, G ;

Baserga, R ;

Iliakis, G ;

Aiken, RD .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2189-2200

[4]

[Anonymous], 2009, SCIENCEDAILY

[5] Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket [J].

Ballard, P ;

Bradbury, RH ;

Harris, CS ;

Hennequin, LFA ;

Hickinson, M ;

Johnson, PD ;

Kettle, JG ;

Klinowska, T ;

Leach, AG ;

Morgentin, R ;

Pass, M ;

Ogilvie, DJ ;

Olivier, A ;

Warin, N ;

Williams, EJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (06) :1633-1637

[6] Tyrosine kinase receptors as attractive targets of cancer therapy [J].

Bennasroune, A ;

Gardin, A ;

Aunis, D ;

Crémel, G ;

Hubert, P .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (01) :23-38

[7] Mammalian protein histidine kinases [J].

Besant, PG ;

Tan, E ;

Attwood, PV .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (03) :297-309

[8] Epidermal growth factor receptor signaling [J].

Bogdan, S ;

Klämbt, C .

CURRENT BIOLOGY, 2001, 11 (08) :R292-R295

[9] The Hsp70 and Hsp60 chaperone machines [J].

Bukau, B ;

Horwich, AL .

CELL, 1998, 92 (03) :351-366

[10] Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer [J].

Carmi, Caterina ;

Mor, Marco ;

Petronini, Pier Giorgio ;

Alfieri, Roberta R. .

BIOCHEMICAL PHARMACOLOGY, 2012, 84 (11) :1388-1399

← 1 2 3 4 5 6 7 8 →